Reduced glucosylceramide in the mouse model of Fabry disease: Correction by successful enzyme replacement therapy

Gene

Volumn 536, Issue 1, 2014, Pages 97-104

  Quinta, Rui ^a,b   Rodrigues, Daniel ^a   Assunção, Marisa ^a   Macedo, Maria Fatima ^a,c   Azevedo, Olga ^b,d   Cunha, Damião ^b   Oliveira, Pedro ^e   Sá Miranda, Maria Clara ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF MINHO   (Portugal)

^c UNIVERSITY OF AVEIRO   (Portugal)

^d Cardiology Department   (Portugal)

^e UNIVERSITY OF PORTO   (Portugal)

Author keywords

Ceramide; Enzyme replacement therapy; Fabry disease; Fabry mice; Glucosylceramide

Indexed keywords

AGALSIDASE ALFA; CERAMIDE; GLUCOSYLCERAMIDE; SPHINGOLIPID;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; HEART; HUMAN; KIDNEY; LIPID METABOLISM; LIVER; LOW DRUG DOSE; MALE; MIDDLE AGED; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SPLEEN; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; WILD TYPE; YOUNG ADULT;

ANIMALIA; MUS;

EID: 84891827179     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.11.073     Document Type: Article

References (58)

1. Aerts J.M., et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:2812-2817.
2. Auray-Blais C., et al. How well does urinary lyso-Gb3 function as a biomarker in Fabry disease?. Clin. Chim. Acta 2010, 411:1906-1914.
3. Balreira A., et al. Anomalies in conventional T and invariant natural killer T-cell populations in Fabry mice but not in Fabry patients. Br. J. Haematol. 2008, 143:601-604.
4. Banikazemi M., et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann. Intern. Med. 2007, 146:77-86.
5. Bekri S., Lidove O., Jaussaud R., Knebelmann B., Barbey F. The role of ceramide trihexoside (globotriaosylceramide) in the diagnosis and follow-up of the efficacy of treatment of Fabry disease: a review of the literature. Cardiovasc. Hematol. Agents Med. Chem. 2006, 4:289-297.
6. Bielawski J., Szulc Z.M., Hannun Y.A., Bielawska A. Simultaneous quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry. Methods 2006, 39:82-91.
7. Blanch L.C., Meaney C., Morris C.P. A sensitive mutation screening strategy for Fabry disease: detection of nine mutations in the alpha-galactosidase A gene. Hum. Mutat. 1996, 8:38-43.
8. Brennan P.J., et al. Invariant natural killer T cells recognize lipid self antigen induced by microbial danger signals. Nat. Immunol. 2011, 12:1202-1211.
9. Chapman M.J. Comparative analysis of mammalian plasma lipoproteins. Methods Enzymol. 1986, 128:70-143.
10. Chatterjee S., Bell W.R., Kwiterovich P.O. Distribution of antithrombin III and glucosylceramide in human plasma lipoproteins and lipoprotein deficient plasma. Lipids 1984, 19:363-366.
11. Chen C.S., Patterson M.C., Wheatley C.L., O'Brien J.F., Pagano R.E. Broad screening test for sphingolipid-storage diseases. Lancet 1999, 354:901-905.
12. Ciron C., et al. Gene therapy of the brain in the dog model of Hurler's syndrome. Ann. Neurol. 2006, 60:204-213.
13. Cressant A., et al. Improved behavior and neuropathology in the mouse model of Sanfilippo type IIIB disease after adeno-associated virus-mediated gene transfer in the striatum. J. Neurosci. 2004, 24:10229-10239.
14. Datta S.C., Radin N.S. Stimulation of liver growth and DNA synthesis by glucosylceramide. Lipids 1988, 23:508-510.
15. Desmaris N., Verot L., Puech J.P., Caillaud C., Vanier M.T., Heard J.M. Prevention of neuropathology in the mouse model of Hurler syndrome. Ann. Neurol. 2004, 56:68-76.
16. Durant B., et al. Sex differences of urinary and kidney globotriaosylceramide and lyso-globotriaosylceramide in Fabry mice. J. Lipid Res. 2011, 52:1742-1746.
17. Ellinwood N.M., et al. Bone marrow transplantation for feline mucopolysaccharidosis I. Mol. Genet. Metab. 2007, 91:239-250.
18. Eng C.M., Ashley G.A., Burgert T.S., Enriquez A.L., D'Souza M., Desnick R.J. Fabry disease: thirty-five mutations in the alpha-galactosidase A gene in patients with classic and variant phenotypes. Mol. Med. 1997, 3:174-182.
19. Frisella W.A., et al. Intracranial injection of recombinant adeno-associated virus improves cognitive function in a murine model of mucopolysaccharidosis type VII. Mol. Ther. 2001, 3:351-358.
20. Fuller M. Sphingolipids: the nexus between Gaucher disease and insulin resistance. Lipids Health Dis. 2010, 9:113.
21. Fuller M., et al. Urinary lipid profiling for the identification of Fabry hemizygotes and heterozygotes. Clin. Chem. 2005, 51:688-694.
22. Futerman A.H., van Meer G. The cell biology of lysosomal storage disorders. Nat. Rev. Mol. Cell Biol. 2004, 5:554-565.
23. Germain D.P. Fabry disease. Orphanet J. Rare Dis. 2010, 5:30.
24. Griffin L.D., Gong W., Verot L., Mellon S.H. Niemann-Pick type C disease involves disrupted neurosteroidogenesis and responds to allopregnanolone. Nat. Med. 2004, 10:704-711.
25. Hammad S.M., et al. Blood sphingolipidomics in healthy humans: impact of sample collection methodology. J. Lipid Res. 2010, 51:3074-3087.
26. Hannun Y.A., Obeid L.M. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat. Rev. Mol. Cell Biol. 2008, 9:139-150.
27. Ioannou Y.A., Zeidner K.M., Gordon R.E., Desnick R.J. Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice. Am. J. Hum. Genet. 2001, 68:14-25.
28. Kartal Yandim M., Apohan E., Baran Y. Therapeutic potential of targeting ceramide/glucosylceramide pathway in cancer. Cancer Chemother. Pharmacol. 2013, 71:13-20.
29. Lee K., et al. A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology 2003, 13:305-313.
30. Macedo M.F., Quinta R., Pereira C.S., Sa Miranda M.C. Enzyme replacement therapy partially prevents invariant Natural Killer T cell deficiency in the Fabry disease mouse model. Mol. Genet. Metab. 2012, 106:83-91.
31. Marsh N.L., Elias P.M., Holleran W.M. Glucosylceramides stimulate murine epidermal hyperproliferation. J. Clin. Invest. 1995, 95:2903-2909.
32. Meikle P.J., Hopwood J.J., Clague A.E., Carey W.F. Prevalence of lysosomal storage disorders. JAMA 1999, 281:249-254.
33. Meikle P.J., et al. Effect of lysosomal storage on bis(monoacylglycero)phosphate. Biochem. J. 2008, 411:71-78.
34. Monserrat L., et al. Prevalence of Fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 2007, 50:2399-2403.
35. Mullen T.D., et al. Selective knockdown of ceramide synthases reveals complex interregulation of sphingolipid metabolism. J. Lipid Res. 2011, 52:68-77.
36. Ohshima T., et al. Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:6423-6427.
37. Poorthuis B.J., et al. The frequency of lysosomal storage diseases in The Netherlands. Hum. Genet. 1999, 105:151-156.
38. Prinetti A., Prioni S., Chiricozzi E., Schuchman E.H., Chigorno V., Sonnino S. Secondary alterations of sphingolipid metabolism in lysosomal storage diseases. Neurochem. Res. 2011, 36:1654-1668.
39. Rodrigues L.G., et al. Neurophysiological, behavioral and morphological abnormalities in the Fabry knockout mice. Neurobiol. Dis. 2009, 33:48-56.
40. Rombach S.M., et al. Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease. Biochim. Biophys. Acta 2010, 1802:741-748.
41. Schiffmann R., Ries M., Timmons M., Flaherty J.T., Brady R.O. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol. Dial. Transplant. 2006, 21:345-354.
42. Schiffmann R., et al. Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1year of agalsidase alfa. Genet. Med. 2013, 15:983-989.
43. Schwab U., et al. Triacylglycerol fatty acid composition in diet-induced weight loss in subjects with abnormal glucose metabolism-the GENOBIN study. PLoS One 2008, 3:e2630.
44. Shabbeer J., Yasuda M., Benson S.D., Desnick R.J. Fabry disease: identification of 50 novel alpha-galactosidase A mutations causing the classic phenotype and three-dimensional structural analysis of 29 missense mutations. Hum. Genomics 2006, 2:297-309.
45. Shayman J.A., et al. Modulation of renal epithelial cell growth by glucosylceramide. Association with protein kinase C, sphingosine, and diacylglycerol. J. Biol. Chem. 1991, 266:22968-22974.
46. Shu L., Shayman J.A. Caveolin-associated accumulation of globotriaosylceramide in the vascular endothelium of alpha-galactosidase A null mice. J. Biol. Chem. 2007, 282:20960-20967.
47. Simons K., Gruenberg J. Jamming the endosomal system: lipid rafts and lysosomal storage diseases. Trends Cell Biol. 2000, 10:459-462.
48. Spada M., et al. High incidence of later-onset Fabry disease revealed by newborn screening. Am. J. Hum. Genet. 2006, 79:31-40.
49. Stanic A.K., et al. Defective presentation of the CD1d1-restricted natural Va14Ja18 NKT lymphocyte antigen caused by beta-d-glucosylceramide synthase deficiency. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:1849-1854.
50. Togawa T., et al. Plasma globotriaosylsphingosine as a biomarker of Fabry disease. Mol. Genet. Metab. 2010, 100:257-261.
51. van Breemen M.J., et al. Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy. Biochim. Biophys. Acta 2011, 1812:70-76.
52. Vedder A.C., et al. The Dutch Fabry Cohort: diversity of clinical manifestations and Gb3 levels. J. Inherit. Metab. Dis. 2007, 30:68-78.
53. Walkley S.U., Vanier M.T. Secondary lipid accumulation in lysosomal disease. Biochim. Biophys. Acta 2009, 1793:726-736.
54. Wang R.Y., Lelis A., Mirocha J., Wilcox W.R. Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet. Med. 2007, 9:34-45.
55. Whitfield P.D., et al. Monitoring enzyme replacement therapy in Fabry disease-role of urine globotriaosylceramide. J. Inherit. Metab. Dis. 2005, 28:21-33.
56. Wittmann J., et al. Newborn screening for lysosomal storage disorders in Hungary. JIMD Rep. 2012, 6:117-125.
57. Wu D., et al. Aging up-regulates expression of inflammatory mediators in mouse adipose tissue. J. Immunol. 2007, 179:4829-4839.
58. Young E., et al. Is globotriaosylceramide a useful biomarker in Fabry disease?. Acta Paediatr. Suppl. 2005, 94:51-54.